PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14551174-0	2003	Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?	Eplerenone	58-68	renin	Homo sapiens	4-9	
20567239-3	2010	Modulation of the renin-angiotensin-aldosterone system (RAAS) provides the rationale for current antihypertensive therapies, including the relatively new agents eplerenone and aliskiren.	Eplerenone	161-171	renin	Homo sapiens	18-23	
15073471-7	2004	Eplerenone offers significant blood pressure reduction with good tolerability in Japanese patients with hypertension, including those with low-renin hypertension.	Eplerenone	0-10	renin	Homo sapiens	143-148	
23314743-9	2013	The increase in plasma renin concentration was significantly greater after eplerenone [+131% (range 61; 231)] than on LCI699 on day 29 [+39% (range 5; 86); P = 0.023].	Eplerenone	75-85	renin	Homo sapiens	23-28	
23314743-11	2013	CONCLUSION: In patients with primary aldosteronism, the effects on blood pressure and plasma potassium and renin concentrations of 4 weeks of eplerenone treatment (50-100 mg b.i.d.)	Eplerenone	142-152	renin	Homo sapiens	107-112	
16169319-0	2005	Effects of eplerenone versus losartan in patients with low-renin hypertension.	Eplerenone	11-21	renin	Homo sapiens	59-64	
16169319-9	2005	CONCLUSIONS: These data show that eplerenone was more effective than losartan in reducing blood pressure in patients with low-renin hypertension.	Eplerenone	34-44	renin	Homo sapiens	126-131	
12422136-8	2002	Eplerenone increased active renin and aldosterone levels, indicating that it blocks the renin-angiotensin-aldosterone system.	Eplerenone	0-10	renin	Homo sapiens	28-33	
12422136-8	2002	Eplerenone increased active renin and aldosterone levels, indicating that it blocks the renin-angiotensin-aldosterone system.	Eplerenone	0-10	renin	Homo sapiens	88-93	
34351585-6	2021	RESULTS: While blood pressure and kidney function were similar in the placebo and eplerenone treatment group during the study period, distinct differences in RAAS regulation occurred: eplerenone treatment resulted in an increase in plasma renin activity, Ang I and aldosterone concentrations, indicating global RAAS activation.	Eplerenone	82-92	renin	Homo sapiens	239-244	
34351585-6	2021	RESULTS: While blood pressure and kidney function were similar in the placebo and eplerenone treatment group during the study period, distinct differences in RAAS regulation occurred: eplerenone treatment resulted in an increase in plasma renin activity, Ang I and aldosterone concentrations, indicating global RAAS activation.	Eplerenone	184-194	renin	Homo sapiens	239-244	
31907345-0	2020	A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.	Eplerenone	66-76	renin	Homo sapiens	121-126	
31907345-13	2020	CONCLUSIONS This is the first case report to present interesting changes of plasma renin activity in a primary aldosteronism patient after switching from eplerenone to esaxerenone.	Eplerenone	154-164	renin	Homo sapiens	83-88	
30418321-6	2019	RESULTS: After 12 weeks, eplerenone decreased the aldosterone renin ratio but did not alter SBP and DBP.	Eplerenone	25-35	renin	Homo sapiens	62-67	
29659888-14	2018	Plasma renin activity and aldosterone levels increased in the eplerenone vs placebo-treated group, demonstrating expected physiology.	Eplerenone	62-72	renin	Homo sapiens	7-12	
25491597-10	2014	Eplerenone 100 mg increased plasma and 24 h urinary aldosterone while stimulating natriuresis and increasing renin activity.	Eplerenone	0-10	renin	Homo sapiens	109-114	
25466242-3	2014	Our study aimed to examine the beneficial effects of addition of a selective aldosterone antagonist, eplerenone, to renin-angiotensin system inhibitors in hypertensive patients with non-diabetic chronic kidney disease.	Eplerenone	101-111	renin	Homo sapiens	116-121	
12589175-6	2003	Eplerenone, a new mineralocorticoid receptor antagonist without antiandrogen side effects, has been an effective antihypertensive in clinical trials and appears to be particularly suitable for low-renin hypertensives.	Eplerenone	0-10	renin	Homo sapiens	197-202	
24961502-0	2015	A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers.	Eplerenone	32-42	renin	Homo sapiens	77-82	
25012174-7	2015	Eplerenone and amiloride each increased plasma aldosterone by 3-fold and renin concentration slightly but did not significantly change eGFR.	Eplerenone	0-10	renin	Homo sapiens	73-78